Evidera
Kim Bailey has a diverse work experience spanning several organizations. From 2023 onwards, they have worked as the Director of Research Operations at Evidera. Prior to that, they held various roles at the Patient-Centered Outcomes Research Institute (PCORI), including Associate Director, Senior Program Officer, and Program Officer in clinical effectiveness and decision science, research synthesis, and clinical effectiveness research. Before joining PCORI, Kim worked at Families USA as a Research Director and Senior Health Policy Analyst. They also served as a Health Policy Analyst and Research Associate at the same organization. Their earliest work experience was as a Bill Emerson National Hunger Fellow at the Congressional Hunger Center.
Kim Bailey has a Master of Science degree in Health Policy, Planning, and Financing from The London School of Economics and Political Science (LSE). Prior to that, Kim obtained a Bachelor of Arts degree in Planning, Public Policy, and Management from the University of Oregon.
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.